Рынок острого респираторного дистресс-синдрома (ОРДС) в США – тенденции отрасли и прогноз до 2029 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок острого респираторного дистресс-синдрома (ОРДС) в США – тенденции отрасли и прогноз до 2029 года

  • Pharmaceutical
  • Published Report
  • Aug 2022
  • Country Level
  • 350 Pages
  • Количество таблиц: 13
  • Количество рисунков: 34

>Рынок острого респираторного дистресс-синдрома (ОРДС) в США по причине (коронавирусное заболевание 2019 года (COVID-19), сепсис, вдыхание вредных веществ, тяжелая пневмония и другие), типу (диагностика и лечение), способу введения (перорально, парентерально и другие), конечному пользователю (больницы, специализированные клиники, уход на дому и другие), каналу сбыта (прямой тендер, больничная аптека, розничная аптека, интернет-аптека и другие) — тенденции отрасли и прогноз до 2029 года.

Анализ и информация о рынке острого респираторного дистресс-синдрома (ОРДС) в США

Ожидается, что рынок острого респираторного дистресс-синдрома (ОРДС) в США значительно вырастет в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 10,6% в прогнозируемый период с 2022 по 2029 год и, как ожидается, достигнет 7 083,46 млн долларов США к 2029 году. Основными факторами, способствующими росту рынка, являются рост распространенности и заболеваемости острым повреждением легких, широкий спектр факторов риска ОРДС и ускорение роста числа пациентов с COVID-19 с ОРДС, рост уровня загрязнения воздуха и заболеваний, связанных с образом жизни, а также рост числа несчастных случаев и травм, вызывающих ОРДС.

Рынок острого респираторного дистресс-синдрома (ОРДС) в США

Рынок острого респираторного дистресс-синдрома (ОРДС) в США

Острый респираторный дистресс-синдром (ОРДС) — это опасное для жизни повреждение легких, при котором жидкость просачивается в легкие. Большинство людей, у которых развивается ОРДС, уже госпитализированы из-за травмы или заболевания, такого как COVID-19. Синдром обычно возникает, когда жидкость скапливается в крошечных эластичных воздушных мешочках легких, называемых альвеолами. Это скопление жидкости приводит к тому, что в кровоток поступает меньше кислорода. Это лишает органы возможности получать достаточное количество кислорода для их нормальной работы. У людей с другими заболеваниями ОРДС развивается в течение нескольких часов или дней после травмы или инфекции. Риск смерти увеличивается с возрастом, и в зависимости от тяжести заболевания пациентам становится тяжело пережить синдром. Тяжелая болезнь или травма, вызывающая повреждение мембранных мешочков легких, приводит к ОРДС. Наиболее распространенными основными причинами указанных заболеваний являются сепсис, вдыхание вредных веществ, тяжелая пневмония, травма головы, груди или другая серьезная травма, коронавирусная болезнь 2019 (COVID-19) и другие.

Отчет о рынке острого респираторного дистресс-синдрома (ОРДС) в США содержит подробную информацию о доле рынка, новых разработках и влиянии внутренних и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического резюме. Наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.

Отчет Метрика

Подробности

Прогнозируемый период

2022-2029

Базовый год

2021

Исторические годы

2020 (Можно настроить на 2019 - 2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Cause  (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia And Others), Type (Diagnosis And Treatment), Route Of Administration (Oral, Parenteral And Others), End User (Hospitals, Specialty Clinics, Home Healthcare And Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy And Others)

Countries Covered

U.S.

Market Players Covered

Gilead Sciences, Inc., Terumo Medical Corporation, Getinge AB., Medtronic, LivaNova PLC, Fresenius SE & Co. KGaA, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd, Fisher & Paykel Healthcare Limited., Hamilton Medical, NIPRO, Pfizer Inc., ResMed, Smiths Medical, WEINMANN Emergency Medical Technology GmbH + Co. KG

Market Definition

The increasing prevalence and incidence of acute lung injury is an important driver for the U.S. acute respiratory distress syndrome (ARDS) market. A wide range of risk factors for ARDS and acceleration in a patient pool of covid-19 with ARDS accelerate market growth. The major restraints may negatively impact the U.S. acute respiratory distress syndrome (ARDS) market. Complications associated with treatments and high cost of device and treatments. The growing geriatric population is expected to provide market opportunities. However, stringent rules and regulations are projected to challenge U.S. acute respiratory distress syndrome (ARDS) market growth.

U.S. Acute Respiratory Distress Syndrome (ARDS) Market Dynamics

Drivers

  • Increasing prevalence and incidence of acute lung injury

Patients with acute lung injuries are being widely reported due to numerous factors like the increasing aged population and the rising number of patients with sepsis and pneumonia, among others. However, most people get diagnosed with lung injuries and acute respiratory distress syndrome only at the late stages. Thereby, the incidence and prevalence of ARDS keep increasing, and the disease has been widely recognized as a major clinical problem worldwide, carrying high morbidity and mortality burden. Hence, increasing prevalence and incidence rates of acute lung injuries and accompanied acute respiratory distress syndrome drive the U.S. acute respiratory distress syndrome (ARDS) market.

  • Wide range of risk factors for ARDS

An enormous range of risk factors is reported for acute respiratory distress syndrome. There are environmental and individual risk factors involved with the syndrome. Some chronic alcohol consumption and active or passive cigarette smoking have been commonly associated. Hence, increasing alcohol consumption irrespective of age leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.

  • Acceleration in patient pool of covid-19 with Acute Respiratory Distress Syndrome (ARDS)

As the world is suffering enormously from COVID-19 infection, there is also a direct correlation between COVID-19 and acute respiratory distress syndrome. Severe cases of COVID-19 disease will ultimately lead to ARDS and pneumonia. This has been proven to be fatal for infected individuals. When the COVID-19-causing virus enters the body, it attaches to the upper airway cells. This sets off an immune response that causes inflammation and leads to symptoms such as cough, sore throat, and fever. In some severe cases, the virus travels beyond the upper airway, moves through the lungs, and ends up in the alveoli. Thereby, the rising number of COVID-19 cases also increases the chance of acute respiratory distress syndrome among people, which is expected to act as a driver for the growth of the acute respiratory distress syndrome market.

  • The rising rate of air pollution and lifestyle-related diseases

Long-term exposure to low to moderate air pollution is associated with a greater risk factor for developing any lung infection, including ARDS. This is a novel and potentially modifiable environmental risk factor for acute respiratory distress syndrome. According to the World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.

  • Increasing accident rates and trauma causing Acute Respiratory Distress Syndrome (ARDS)

Major trauma caused by accidents is a well-known risk factor for the development of ARDS. Acute respiratory distress syndrome can result from an injury to the body by creating inflammation of the pancreas, breathing contents of the stomach into the lung, blood transfusions, house fire and smoke inhalation, serious infection, drowning trauma, and severe reaction to medications. Even car accidents are a cause of ARDS. Hence, inhalation of smoke releases certain materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS.

Рынок острого респираторного дистресс-синдрома (ОРДС) в США

Opportunities

  • Growing geriatric population

The 'world's geriatric population is increasing at a rapid rate. Older people have become an increasingly prevalent population of intensive care admissions. As per an article on National Center for Biotechnology Information (NCBI), the mortality rate associated with acute respiratory distress syndrome (ARDS) has been 69% to 80% reported among the elderly population, making it riskier for geriatric people. Thus, the growing pace of the older population demonstrates the escalation in demand for acute respiratory distress syndrome treatments as they are more vulnerable to severe respiratory illness due to their weak immune system. It is anticipated that the -increasing geriatric population, which is expected to rise in future years worldwide, creates an opportunity for market growth in the forecast period.

  • Rising healthcare expenditure

Healthcare expenditure has increased worldwide as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for acute respiratory distress syndrome, as the disorder has been highly prevalent in recent years. Growing healthcare expenditure is also beneficial for further economic and healthcare sector growth. It is primarily fruitful as it significantly affects the development of better and advanced therapeutic options with ventilators and other ARDS treatment devices.

  • Strategic initiatives by market players

With increasing rates of infectious diseases such as COVID-19 and chronic diseases like lung cancer, the simultaneous burden of 'syndrome like ARDS is widely seen globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives these players take. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market. These strategic product launches, acquisitions, and mergers done by major companies in the acute respiratory distress syndrome market have opened up opportunities for companies in various regions. This strategy is allowing the companies to strengthen their footprints in the market.

  • Improving awareness regarding Acute Respiratory Distress Syndrome (ARDS)

Since acute respiratory distress syndrome has multiple different causes, it is usually ignored under common causes of death. The requirement of advanced technical treatment and proper awareness of the condition can substantially decline ARDS incidence. As timely diagnosis and prevention are crucial to preventing or recovering faster, the public's attention is most important. Current government and organizations have broadened the scope of lung injury research to include primary prevention of ARDS and reduce the morbidity or mortality rate for the syndrome. Thereby, increasing awareness regarding ARDS by diverse 'association's support enhances the U.S. acute respiratory distress syndrome 'market's opportunity for wide growth in the future.

Restraints/Challenges

  • Complications associated with treatments

Acute respiratory distress syndrome is a clinical condition requiring proper and timely treatment and cares to prevent mortality and morbidity rates. However, during the treatment of ARDS, the patients might face many complications in the hospitals. Though there are treatments for ARDS helping people survive, the complications associated during treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more. These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.

  • High cost of device and treatments

Though acute respiratory distress syndrome is getting a wide range of advanced treatment options, the cost of treatment for longer is quite difficult for average-income people to afford. The utilization of critical care and intensive care unit services is increasing worldwide, and its expensive cost is a major concern in the current healthcare system. Patients with ARDS are commonly required to have long hospitalizations with frequent monetarization and ventilation usage, consuming a significant amount of healthcare resources. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.

  • Lack of skilled workforce

The sudden COVID-19 crisis has created various challenges to be faced by a healthcare organization, including a workforce shortage. The pandemic massively struck developed countries like the U.S. They initiated multiple ways to overcome such challenges, but news articles reported that the countries were dealing with staffing shortages. There were shortages of nurses even before the pandemic began in the U.S., as the region has a high population with respiratory disorders. Therefore, the lack of appropriately skilled and trained nurses in the ICU will be a more remarkable restraint expected to hamper the growth of the acute respiratory distress syndrome (ARDS) market.

  • Stringent rules & regulations

The use of ventilators across the globe is rapidly increasing, with the growth of the aged population and several acute lung diseases, including acute respiratory distress syndrome, which is preventable by early diagnosis and timely treatments. At the same time, the players of the acute respiratory distress syndrome manufacturers in the market have to follow specific regulations to get approval from the upper authorities to launch the product like mechanical ventilators or humidifiers. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. For example, the U.S. Food and Drug Administration (FDA) regulates respiratory ailment products in the U.S. Therefore, the stringent rules & regulations for product approval challenge the market's growth.

  • Multiple challenges faced by ICU nurses

The intensive care units have many challenges to face during the pandemic due to a large patient pool and fewer hospital resources. Since the first wave of COVID-19, the hospitals have increased the capacity and potential of 'ICUs, which has led to increased working hours for ICU health care providers. The nurses dealing in ICU are always in fear due to multiple reasons for handling infected patients. Therefore, the most significant challenge is the difficulties faced by nurses and other healthcare providers dealing with acute respiratory distress syndrome and severe acute respiratory syndrome. Organizations are trying to overcome them with new innovative ideas and appointing more workforces.

Recent Development

  • In July 2020, Gilead Sciences, Inc. initiated clinical testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19. This testing helped the company enhance its antiviral product portfolio, thereby strengthening its footprint on the market

U.S. Acute Respiratory Distress Syndrome (ARDS) Market Scope

U.S. acute respiratory distress syndrome (ARDS) market is categorized based on cause, type, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Cause

  • Coronavirus Disease 2019 (COVID-19)
  • Sepsis
  • Inhalation Of Harmful Substances
  • Severe Pneumonia
  • Others

Based on the cause, the U.S. acute respiratory distress syndrome (ARDS) market is classified into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others.

Type

  • Diagnosis
  • Treatment

Based on type, the U.S. acute respiratory distress syndrome (ARDS) market is classified into diagnosis and treatment.

Route of Administration

  • Oral
  • Parenteral
  • Others

Based on route of administration, the U.S. acute respiratory distress syndrome (ARDS) market is classified into oral, parenteral, and others.

End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Based on end-user, the U.S. acute respiratory distress syndrome (ARDS) market is classified into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Рынок острого респираторного дистресс-синдрома (ОРДС) в США

Based on distribution channel, the U.S. acute respiratory distress syndrome (ARDS) market is classified into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others.

Competitive Landscape and U.S. Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

Конкурентная среда рынка острого респираторного дистресс-синдрома (ОРДС) в США содержит сведения о конкурентах. Включены сведения о компании, финансах компании, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, производственных площадках и объектах, сильных и слабых сторонах компании, запуске продукта, испытаниях продукта, одобрении продукта, патентах, широте и широте продукта, доминировании приложений, жизненно важной кривой технологий. Приведенные выше данные относятся только к фокусу компаний, связанному с рынком острого респираторного дистресс-синдрома (ОРДС) в США.

Некоторые из видных участников рынка острого респираторного дистресс-синдрома (ОРДС) в США: Gilead Sciences, Inc., Terumo Medical Corporation, Getinge AB., Medtronic, LivaNova PLC, Fresenius SE & Co. KGaA, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd, Fisher & Paykel Healthcare Limited., Hamilton Medical, NIPRO, Pfizer Inc., ResMed, Smiths Medical, WEINMANN Emergency Medical Technology GmbH + Co. KG.

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Рыночные данные анализируются и оцениваются с использованием рыночных статистических и когерентных моделей. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в рыночном отчете. Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Помимо этого, модели данных включают сетки позиционирования поставщиков, анализ временной линии рынка, обзор и руководство рынка, сетки позиционирования компании, анализ доли компании на рынке, стандарты измерения, сравнение США и регионов и анализ доли поставщиков. Пожалуйста, запросите звонок аналитика в случае дальнейшего запроса.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CAUSE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES MODEL

4.3 PIPELINE ANALYSIS

5 INSURANCE REIMBURSEMENT

5.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)

5.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION

5.3 ABBOTT CODING GUIDE FOR ECMO

5.4 CERN HEALTH INSURANCE SCHEME

5.5 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)

5.6 AMERICAN HOSPITAL ASSOCIATION

5.7 CONCLUSION

6 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS

6.1 REGULATION IN U.S.

6.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA

6.3 LABELING OF MODIFIED DEVICES

7 COUNTRY SUMMERY

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY

8.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS

8.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS

8.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES

8.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS

8.2 RESTRAINTS

8.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS

8.2.2 HIGH COST OF DEVICE AND TREATMENTS

8.2.3 LACK OF SKILLED WORKFORCE

8.3 OPPORTUNITIES

8.3.1 GROWING GERIATRIC POPULATION

8.3.2 RISING HEALTHCARE EXPENDITURE

8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

8.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME

8.4 CHALLENGES

8.4.1 STRINGENT RULES & REGULATIONS

8.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES

9 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE

9.1 OVERVIEW

9.2 CORONAVIRUS DISEASE 2019 (COVID-19)

9.3 SEPSIS

9.4 INHALATION OF HARMFUL SUBSTANCES

9.5 SEVERE PNEUMONIA

9.6 OTHERS

10 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE

10.1 OVERVIEW

10.2 DIAGNOSIS

10.2.1 IMAGING TESTS

10.2.1.1 CHEST X-RAY

10.2.1.2 CT SCAN

10.2.1.3 ULTRASOUND

10.2.1.4 OTHERS

10.2.2 BLOOD TEST

10.2.3 RESPIRATORY RATE

10.2.4 SPO2 TEST

10.2.5 OTHERS

10.3 TREATMENT

10.3.1 MECHANICAL VENTILATION

10.3.1.1 HIGH-FLOW NASAL O2

10.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE

10.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE

10.3.1.4 PRONE POSITIVE VENTILATION

10.3.1.5 OTHERS

10.3.2 CORTICOSTEROIDS

10.3.2.1 METHYLPREDNISOLONE

10.3.2.2 DEXAMETHASONE

10.3.2.3 OTHERS

10.3.3 ANTIVIRAL MEDICATION

10.3.3.1 REMDESIVIR

10.3.3.2 COMBINATION DRUGS

10.3.3.3 OTHERS

10.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

10.3.5 TOCILIZUMAB

10.3.6 OTHERS

11 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 PARENTERAL

11.2.1 INTRAVENOUS

11.2.2 INTRAMUSCULAR

11.3 ORAL

11.4 OTHERS

12 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 SPECIALTY CLINICS

12.4 HOME HEALTHCARE

12.5 OTHERS

13 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 HOSPITAL PHARMACY

13.4 RETAIL PHARMACY

13.5 ONLINE PHARMACY

14 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: U.S

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 GILEAD SCIENCES INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUS ANALYSIS

16.1.3 PRODUCT PORTFOLIO

16.1.4 RECENT DEVELOPMENT

16.2 TERUMO CORPORATION

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUS ANALYSIS

16.2.3 PRODUCT PORTFOLIO

16.2.4 RECENT DEVELOPMENT

16.3 GETINGE AB

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUS ANALYSIS

16.3.3 PRODUCT PORTFOLIO

16.3.4 RECENT DEVELOPMENT

16.4 LIVANOVA PLC

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 MEDTRONIC

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 DRÄGERWERK AG & CO. KGAA

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 F. HOFFMANN-LA ROCHE LTD

16.7.1 COMPANY SNAPSHOT

16.7.2 RECENT ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 FISHER & PAYKEL HEALTHCARE LIMITED

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 FRESENIUS SE & CO. KGAA

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUS ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 HAMILTON MEDICAL

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 NIPRO

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUS ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 PFIZER INC.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUS ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 RESMED

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 SMITHS MEDICAL

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUS ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Список таблиц

TABLE 1 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS

TABLE 2 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 3 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 U.S. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 U.S. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 U.S. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 11 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 12 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 13 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

Список рисунков

FIGURE 1 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 2 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION

FIGURE 3 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS

FIGURE 4 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COUNTRY MARKET ANALYSIS

FIGURE 5 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 11 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

FIGURE 14 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2021

FIGURE 15 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2022-2029 (USD MILLION)

FIGURE 16 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2022-2029)

FIGURE 17 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 18 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2021

FIGURE 19 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 20 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 21 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 24 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2021

FIGURE 27 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DISTRIBUTION CHANNEL, 2021

FIGURE 31 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 32 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 33 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The major companies which are operating in the market are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare, Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS and among others.
Rise in market players and the availability of advanced products are flourishing the growth of the U.S. Acute Respiratory Distress Syndrome (ARDS) market.
The U.S. Acute Respiratory Distress Syndrome (ARDS) Market is to grow at a CAGR of 10.6% during the forecast by 2029.
The U.S. Acute Respiratory Distress Syndrome (ARDS) Market value is expected USD 7,083.46 million by 2029.